Conexeu Sciences Issues Update On Regulatory And Manufacturing Program Supporting Planned FDA 510(k) Premarket Notification For Ten Minute Tissue, Lead Wound Care Device Candidate
Company advances manufacturing scale-up, regulatory testing and preclinical work supporting its planned FDA 510(k) submission in the first quarter of 2027. Multiple scaled-up batches of CXU™ material met predefined
Conexeu is moving forward with its wound care product. The company completed manufacturing tests and plans to ask FDA for approval in early 2027.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.